Guidelines for the Pharmacological Management of Chronic Pain in Primary Care. December 2012
|
|
- Mavis Hoover
- 6 years ago
- Views:
Transcription
1 Guidelines for the Pharmacological Management of Chronic Pain in Primary Care December 2012 NHS Portsmouth CCG Fareham and Gosport CCG South Eastern Hampshire CCG 1
2 Guidelines for the Pharmacological Management of Chronic Pain in Primary Care Purpose To facilitate the appropriate Primary Care management of adults suffering with chronic pain. Introduction Pain is one of the most common reasons that patients present to Primary Care and it is important that GPs optimise the pharmacological management of patients pain BEFORE considering referral to a Community Pain Self Management Service. It is kwn that there are widespread changes within the nervous system that give rise to persistent pain (Siddall, 1997). According to the British Pain Society, one in seven people is thought to suffer from persistent pain and twenty percent of those report suffering for more than 20 years. People with pain consult their doctor up to five times more frequently than others, resulting in nearly 5 million GP appointments each year. Poorly managed chronic pain can affect quality of life for sufferers and their carers, leading to helplessness, isolation, depression and family breakdown. It is important that the GP optimises the pharmacological management of patients pain before referring to the Community Chronic Pain Self Management Service Scope of Guidelines These Guidelines are to assist in the management of chronic pain in all patients aged 18 years or over. Chronic pain is continuous, long-term pain of more than 12 weeks or after the time that healing would have been thought to have occurred in pain after trauma or surgery This document does t cover the management of pain associated with cancer For use by all n-specialist prescribers within Primary Care. Recommendations This guidance is intended to guide management and recommendations are based on established practice throughout the UK and relevant NICE guidance. References are listed below. It should be emphasised that medicines play only a mir part in managing persistent pain. Maintaining fitness, pacing activities and a generally healthy lifestyle are important. Nonpharmacological methods of pain relief such as TENS, acupuncture, physical methods for the reduction of muscle spasm are equally important. All patients should be screened for common mental health problems that may result from experiencing difficult to control pain. A mental health needs assessment should be made before starting strong opioids. References Opioids for Persistent Pain: Good Practice. January The British Pain Society Finnerup N B, Otto M, McQuay H J, Jensen T S, and Sindrup S H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain, 2005, 118(3): The Oxford Pain Internet Site. NICE CG 88 Low back pain: Early management of persistent n-specific low back pain,may 2009 NICE CG 96 Neuropathic pain: The pharmacological management of neuropathic pain in adults in nspecialist settings, March 2010 NICE CG 59 Osteoarthritis: The care and management of osteoarthritis in adults February 2008 Page 2 of 9
3 Algorithm for the Pharmacological Management of Persistent Pain Does the patient have chronic pain? (Pain continuing after healing or in the absence of injury) See Pain Clinic referral guidelines (page 9) Refer as appropriate yes Is there a component of neuropathic pain? (e.g. shingles-like pain) See Neuropathic Pain Guideline (Appendix 1 page 7) Is there serious medical pathology? (Red Flags - page 8) yes yes Commence a trial of medication based upon the Neuropathic Pain Guideline (Appendix 1) Commence a trial of regular medication to weak opioid level based on the Analgesic Ladder (page 3). Encourage activity Has pain settled to a reasonable level? Is the patient compliant with the medication regimen? yes Step-up to strong opioid based on the Analgesic Ladder See prescribing tes to enhance concordance Check Psychosocial factors (Yellow flags) yes yes Refer to Community Chronic Pain Self Management Service (where available) Has pain settled to a reasonable level? Consider exercise programme to maintain fitness/flexibility and reduce flare ups If appropriate management does t improve pain management consider referral to Community Chronic Pain Self Management Service (where available) If reasonable pain relief and reactivation achieved, consider trial of reduction in analgesia in step-wise fashion over several weeks Yes No Page 3 of 9
4 Analgesic Ladder - Assess each change to analgesic regimen after 4 6 weeks Step 1 Non-opioid analgesic / baseline analgesia Paracetamol 1g four times a day - Continue as patient moves through Steps 2 and 3 (Consider addition of NSAID e.g. ibuprofen or naproxen but only if there is a is a recurrent inflammatory process involved and beware renal, GI, and cardiovascular risks) Step 2 Opioids for moderate to severe pain First Line: Codeine / Dihydrocodeine 30mg four times a day (maximum 240mg daily dose) Up to 10% of caucasians may be unable to metabolise codeine to morphine dihydrocodeine does t rely on this process for action. Co-drugs e.g. co-dydramol, co-codamol may improve compliance in a responsive patient but may have a higher incidence of side-effects and are more difficult to titrate to need due to the fixed doses of each component. Co-drugs are better reserved for use once the efficacy of each component is established Second line alternatives to codeine/dihydrocodeine: Tramadol Starting dose 50mg up to four times a day. Increased up to maximum of 100mg four times a day Tramadol is an alternative opioid and possesses serotonergic and adrenergic properties too. It is generally t well tolerated in elderly patients and can cause psychiatric reactions in patients of all ages. Drowsiness is a commonly reported side-effect. It can lower seizure threshold so should be used with care in epileptic patients. Buprerphine Patch (BuTrans ) Starting Dose 5mcg/hour increased to a maximum of 20mcg/hour Offers an alternative where oral analgesia is t possible or t tolerated. Adverse effects similar to other opioids. Patches are applied ONCE every 7 days. Patches are expensive compared to oral preparations. All opioids should be started at the lowest possible dose (equivalence) and titrated up. Tolerability: Nausea, dizziness can be dose related. Start at low doses and increase slowly. Slow release preparations may be better tolerated; however DHC Continus and Tramadol SR are more expensive. Tramadol / paracetamol combination products (e.g. Tramacet ) are NOT recommended. Step 3 Opioids for severe pain 1 st LINE Morphine SR (Zomorph capsules) 20mg twice daily Increase dose by more than 10mg twice daily at a time 2 ND LINE - (Change opioid if adequate analgesia but intolerable side-effects with morphine) Oxycodone MR or Tapentadol SR may have reduced incidence of hallucinations and nausea Fentanyl patch may accumulate less in renal failure and have reduced incidence of constipation. Only to be used in patients who are established on a regular, steady dose of opioid. Buprerphine (Transtec patches) may accumulate less in renal failure and reduced incidence of constipation. Dose equivalence is less reliable however, so other opioids are preferred before buprerphine. If opioid use does t improve function or doses start escalating due to poor effect, it is likely the patient has n-opioid responsive pain and opiods should be tailed off and stopped. Opioids should be reviewed every six months and doses reduced as soon as possible to the lowest effective dose. Additional information to consider Regular laxatives for patients taking opioids (moderate severe pain) e.g magnesium hydroxide or docusate sodium and senna. Encourage regular fluid intake. Dietary changes alone rarely improve opioid-induced constipation. Anti-emetics during first 2 weeks of opioid therapy, especially in opioid naïve patients. Cyclizine rmally first line Consider n-drug therapies education, explanation and reassurance. Pacing activities, physical therapies, TNS machine, Non-steroidal anti-inflammatory drugs are t appropriate for chronic pain management unless there is a recurrent inflammatory process involved Page 4 of 9
5 Strong opioids for persistent n-cancer pain Dosage equivalence table These dose equivalences are intended only as an approximate guide; patients should be carefully monitored after ANY change in mediation and dose titration may be required to avoid either underdosing or excessive dosing. The order of products in the table below does t imply any order of preference. Starting Dose Titrate slowly ( more frequently than every 2 weeks) FIRST LINE Morphine Sulphate MR (Zomorph capsules) 10mg every 12 hours 20mg every 12 hours 30mg every 12 hours 40mg every 12 hours 50mg every 12 hours Buprerphine transdermal patches (Butrans ) BuTrans 5 microg/hr changed ONCE every 7 days BuTrans 10 microg/hr changed ONCE every 7 days BuTrans 20 microg/hr changed ONCE every 7 days Transtec 35 microg/hr changed TWICE weekly Transtec 52.5 microg/hr changed TWICE weekly Fentanyl transdermal patches (Matrifen ) Oxycodone MR tablets (Oxycontin ) 5mg every 12 hours Tapentadol SR (Palexia SR ) 12 microg/hr changed every 3 days 10mg every 12 hours 50mg every 12 hours 25 microg/hr changed every 3 days 15mg every 12 hours 20mg every 12 hours 25mg every 12 hours 100mg every 12 hours Suggested MAXIMUM DOSE for n-cancer pain initiated in primary care. Seek specialist advice if patient requiring higher doses. Maximum dose in primary care 60mg every 12 hours Transtec 70 microg/hr changed TWICE weekly 50 microg/hr changed every 3 days 30mg every 12 hours 150mg every 12 hours 5
6 ADDITIONAL GUIDANCE ON USE OF OPIOIDS FOR PERSISTENT NON-CANCER PAIN Before initiating opioid therapy Use only as part of a wider management plan aimed at reducing disability and improving quality of life. Set individualised goals of therapy for each patient. Make clear to patients that if trial is unsuccessful then opioid treatment will be discontinued. Give realistic expectations. Opioids are unlikely to give complete pain relief. Some pains do t respond to opioids. Treatment success is demonstrated by functional improvement Cautions Renal impairment. Dose reduction for egfr < 30 ml/min. Seek specialist advice. Patients should t drive when starting opioids, adjust dose or if they feel unfit to drive. Patients should inform DVLA and their car insurance company. Prescribing Be clear who is responsible for prescribing ideally a single prescriber. Use regular dosing with oral modified release preparations only, NOT immediate release formulations. Morphine sulphate MR (Zomorph ) should be the first-line opioid. Start with a low dose and slowly titrate according to analgesia and side effects, increasing more frequently than every two weeks. Discuss alternative strategies for exacerbations of pain short acting opioids are t appropriate for the majority of patients. Review regularly. Initially at least monthly, more often if there are concerns. When on a stable dose monitor at least bi-annually. Switching opioids Efficacy and adverse effects are similar for all opioids, although patients may tolerate one opioid better than ather. When switching, consider reducing dose by 25-50% to allow for incomplete cross tolerance and monitor regularly. See table and approximate opioid equivalences overleaf. Withdrawal symptoms (e.g. sweating, yawning and abdominal cramps) occur if an opioid is stopped/dose reduced abruptly. This is common with tramadol and can occur with weak opioids even after a short course. Adverse effects Constipation: Common. Minimise by encouraging lots of fluids, fruit and fibre. Always prescribe laxatives (senna two tablets at night when required and docusate sodium 200 mg twice a day). If constipation problematic with morphine, transdermal fentanyl is the preferred alternative. Possible long term endocrine / immulogical effects. Consider measuring plasma testosterone or oestradiol after 6 months, seek advice if levels low. There are currently insufficient data to quantify the risks of long term opioid therapy. Concerns relate to the effects of opioids on the endocrine and immune systems and the risk of inducing a hyperalgesic syndrome. Dependence and addiction Physical dependence is inevitable. Addiction (psychological dependence and craving) is rare. Pharmacological effects of physical dependence and ease of discontinuation helped by limiting maximum dose (see overleaf). More information For doctors is available at For patients is available at 6
7 Pharmacological Management of Neuropathic Pain (use in addition to, or instead of, conventional analgesics) Appendix 1 Step 1 Non-opioid analgesic / baseline analgesia Paracetamol 1g four times a day Continue as patient moves through Steps 2-3 Step 2 Can be combined with Step 3 to optimise treatment Step 3 Tricyclic antidepressant (TCAs, usually first choice, unlicensed indication) Amitriptyline Week 1 Week 2 Week 3 Week 4 Week 5 10mg 20mg 30mg 40mg 50mg Analgesic effect is separate from antidepressant effect Best taken in the evening to reduce hangover effect e.g. 6-8pm Slowly titrate to reduce side-effects but ensure titration occurs even if dose is later reduced Normal maximum dose is 50mg daily but up to 100mg can be used if patient is deriving benefit with limited side-effects Side-effect profiles are similar but alternative TCAs e.g. imipramine or rtriptyline, may be used if patient responds to amitriptyline but cant tolerate side effects. No TCAs are licensed for the treatment of neuropathic pain. Anticonvulsant If TCAs are contraindicated or lancinating pain ( electric shocks ) Gabapentin Week 1 Week 2 Week 3 Week 4 Morning 300mg 300mg 300mg Midday 300mg 300mg Night 300mg 300mg 300mg 600mg Continue increasing as above to maximum 900mg three times a day determined by efficacy and side-effects Gabapentin is renally eliminated. Reduce dose in renal impairment 2 nd Line Pregabalin, only if gabapentin gives good effect but side-effects cant be tolerated (consider starting titration at lower dose in elderly or in patients who are susceptible to side-effects). Day1 Day 4 Day 8 Day 12 Morning 75mg 75mg 150mg Night 75mg 75mg 150mg 150mg Titration can be continued to a maximum of 300mg twice daily determined by efficacy and side-effects. Do NOT prescribe pregabalin more than twice a day. Pregabalin is renally eliminated. Reduce dose in renal impairment Step-wise reduction of both gabapentin and pregabalin is required if ineffective and/or t tolerated ON RECOMMENDATION OF SPECIALIST ONLY Lidocaine plaster (Versatis ) for focal neuralgia where other treatment options have failed or cant be used due to co-morbidities etc. A maximum 4 week trial should be used to establish efficacy and the prescription should cease if good effect is t established. Plasters can be cut to match the size of the affected focal site; therefore, t all patients will require a full plaster to be used each day. Duloxetine (Cymbalta ) 3 rd line where other neuropathic agents have failed or for a clear diagsis of diabetic neuropathy. Page 7 of 9
8 Red and Yellow Flags Appendix 2 Red flags are clinical indicators of possible serious underlying conditions requiring further medical intervention. Red flags were designed for use in acute low back pain, but the underlying concept can be applied more broadly in the search for serious underlying pathology in any pain presentation. YYeel lloow flf laaggss are psychosocial indicators suggesting increased risk of progression to long-term distress, disability and pain. Yellow flags were designed for use in acute low back pain. In principle they can be applied more broadly to assess likelihood of development of persistent problems from any acute pain presentation. They can be summarised as distress, disability, dependence and drugs (4Ds). The STarT Back Screening tool is designed to screen Primary Care patients with low back pain for progstic indicators that are relevant to initial decision making. Click here for link to STarT Back Tool Red Flags Differential diagsis Red Flags from patient history Red Flags from examination Possible fracture Possible tumour or infection Possible significant neurological deficit Major trauma Mir trauma in elderly or osteoporotic Age < 20 or > 50 years old History of cancer Constitutional symptoms (fever, chills, weight loss) Recent bacterial infection Intraveus drug use Immusuppression Pain worsening at night or when supine Severe or progressive sensory alteration or weakness Bladder or bowel dysfunction Evidence of neurological deficit (in legs or perineum in the case of low back pain) The presence of red flags in acute low back pain suggests the need for further investigation and possible specialist referral as part of the overall strategy. Yellow Flags Attitudes and Beliefs Emotions and Behaviour Other psychosocial factors Pain is harmful or severely disabling Expectation that passive treatment rather than active participation will help Feeling that -one believes the pain is real may relate to previous encounters with health professionals Fear-avoidance behaviour (avoiding activity due to fear of pain) Low mood and social withdrawal Poor family relationships or history of abusive relationships Financial concerns particularly related to ill-health or ongoing pain Work related factors e.g. conflict over sick leave, ability to perform current job tasks Ongoing litigation related to persistent pain condition Appendix 3 Page 8 of 9
9 Referral Criteria for Pain Clinic at Portsmouth Hospitals NHS Trust The PHT Pain Clinic is accepting referrals for patients meeting the following criteria:- Patients with cancer struggling with pain control Patients developing or having suspected Complex Regional Pain Syndrome (CRPS) Neuropathic pain (as per NICE guidance) Trigeminal neuralgia Spinal patients suffering acute brachalgia or sciatica will be seen via the Spinal Pathway, and may be offered injection treatment according to clinical evidence. Patients with acute deterioration of symptoms of spinal claudication from spinal stesis will be considered for epidural, via the Spinal Pathway. GPs are also advised to consider using Advice and Guidance (via Choose and Book) as an alternative to referral Author: Katie Hovenden, Associate Director Medicines Management and CCG Development NHS Portsmouth CCG With grateful thanks to Emma Davies, Pharmacist with a Specialist Interest in Pain Management who produced the original guidance for the Basingstoke, Southampton and Winchester DPC. This was used as starting point for this guidance for use within the Portsmouth and South East Hampshire health ecomy. Approved by: Portsmouth and South East Hampshire Area Prescribing Committee, December 2012 Review Date: December 2014 Page 9 of 9
Berkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationPain Management Documents
Pain Management Documents Prescriber and Patient Resources Non-cancer Pain Guidance Neuropathic Pain Guidance Stopping or Switching low strength Buprenorphine Patches Red and Yellow Flags Medicines Management
More informationGuidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationGateshead Pain Guidelines for Chronic Conditions
Gateshead Pain Guidelines for Chronic Conditions Effective Date: 13.2.2013 Review Date: 13.2.2015 Gateshead Pain Guidelines: Contents PAIN GUIDELINES Chronic Non-Malignant Pain 5 Musculoskeletal Pain 6
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationPRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN
NORTH OF TYNE GUIDELINES FOR: PRIMARY MANAGEMENT OF DRUG PRESCRIBING IN NON-MALIGNANT PAIN (EXCLUDING DETAILED RECOMMENDATIONS FOR LONG TERM STRONG OPIATES) February 2015 (minor update April 2017) 1 CONTENTS
More informationYour A-Z of Pain Relief A guide to pain relief medicines. We care, we discover, we teach
Your A-Z of Pain Relief A guide to pain relief medicines We care, we discover, we teach Which pain medicines are you taking? Abstral (see Fentanyl Instant Tablets) Amitriptyline 5 Brufen (see Ibuprofen)
More informationNeuropathic pain MID ESSEX LOCALITY
Neuropathic pain Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. A. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) i Read questions to
More informationManagement of neuropathic pain (non-malignant) Medicines Initiation Protocol
Introduction Management of neuropathic pain (non-malignant) Medicines Initiation Protocol Pain is one of the most common reasons that patients present to Primary Care It is known that there are widespread
More informationCommissioning Policy Individual Funding Request
Commissioning Policy Individual Funding Request Referrals to Secondary Care Pain Services for Assessment and Treatment Criteria Based Access Policy Date Adopted: Version: Development Individual Funding
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationPersistent Pain Resources. Educational Slide Set
Persistent Pain Resources Educational Slide Set October 216 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG)
More informationPatient Information Leaflet. Opioid leaflet. Produced By: Chronic Pain Service
Patient Information Leaflet Opioid leaflet Produced By: Chronic Pain Service November 2012 Review due November 2015 1 Your Pain Specialist has recommended treatment with strong pain killers (opioids).
More informationSwitching Tramacet to paracetamol alone or paracetamol and codeine
Bulletin 62 February 2014 Community Interest Company Switching Tramacet to paracetamol alone or paracetamol and codeine This is one of a number of bulletins providing further information on medicines contained
More information21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content
Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationAppendix 4C: Guidance on the Management of Chronic Non- Malignant Pain
Appendix 4C: Guidance on the Management of Chronic Non- Malignant Pain Chronic Pain Patient reporting persistent pain not responded to treatment > 3months. Serious causes should be excluded Pain is a complex
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationPain CONCERN. Medicines for long-term pain. Opioids
Pain CONCERN Medicines for long-term pain Opioids Opioids are a group of medicines that come from the extract of poppy seeds or other medicines that work in the same way. Types of opioid The first opioids
More informationOPIOIDS FOR PERSISTENT PAIN: INFORMATION FOR PATIENTS
OPIOIDS FOR PERSISTENT PAIN: INFORMATION FOR PATIENTS This leaflet aims to help you understand your pain, so that you can work with your health care team to self-manage your symptoms and improve your quality
More informationDoncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary
Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationPrescribing drugs of dependence in general practice, Part C
HO O Prescribing drugs of dependence in general practice, Part C Key recommendations and practice points for management of pain with opioid therapy H H HO N CH3 Acute pain Acute pain is an unpleasant sensory
More informationChronic Non Malignant Pain Opioid Guideline
CLINICAL GUIDELINE Chronic Non Malignant Pain Opioid Guideline A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised
More informationOpioids in Palliative Care
Opioids in Palliative Care Brooke Building Palliative Care Team 0161 206 4609 All Rights Reserved 2017. Document for issue as handout. What are strong opioids? Strong opioids are painkillers which are
More informationPain Management for Adult sickle cell disease patients: Information for patients, relatives and carers
Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers Why you should read this leaflet This leaflet will give you the information necessary to manage your
More informationThe pain of it all. Rod MacLeod MNZM. Hibiscus Hospice, Auckland and University of Auckland
The pain of it all Rod MacLeod MNZM Hibiscus Hospice, Auckland and University of Auckland Definition of PAIN An unpleasant sensory and emotional experience which we primarily associate with tissue damage
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationPrimary care review of Tramadol Prescribing
Primary care review of Tramadol Prescribing Aim of the Audit To ensure the prescribing of tramadol is safe, appropriate and regularly reviewed, in line with local chronic pain guidelines 1 Background Tramadol
More informationPain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17
Pain Christine Illingworth Community Nurse St Luke s Hospice 17/5/17 What is pain? Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage Pain is whatever
More informationMedicines to treat pain in adults. Information for patients and carers
Medicines to treat pain in adults Information for patients and carers It is common to feel some pain after having an operation (surgery), trauma or an infection. Controlling pain is an important part of
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationOPIOIDS AND NON-CANCER PAIN
Ch05.qxd 1/6/04 4:33 PM Page 77 CHAPTER 5 OPIOIDS AND NON-CANCER PAIN Background 78 Side-effects of opioids 78 Tolerance, physical dependence and addiction 79 Opioid-induced pain 79 Practical issues 80
More informationAdult Opioid Prescribing Guidelines for Acute or Persistent Pain
Adult Opioid Prescribing Guidelines for Acute or Persistent Pain Author: Sponsor/Executive: Responsible committee: Consultation & Approval: (Committee/Groups which signed off the policy, including date)
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationPersistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014
Persistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014 Dr Iain Brew Vice Chair RCGP SEG Health & Justice CRG Member Special Considerations General reluctance
More informationOxycodone use still increasing
Oxycodone use still increasing 14 BPJ Issue 36 In BPJ 24 (Nov, 2009) we reported that oxycodone use in New Zealand had been steadily rising. Latest pharmaceutical dispensing data suggest that oxycodone
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationPain relief at home. Information for patients, families and carers
Pain relief at home Information for patients, families and carers 3 Contents Page 2 Page 3 Page 4 Page 5 Page 7 Page 8 Introduction to pain relief Common pain relief medicines and their side effects More
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationPain relief to take home after your surgery
Pain relief to take home after your surgery Information for patients from the Department of Anaesthesia This factsheet explains: About pain and pain relief at home after surgery. Which pain relief drugs
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More information10/08/59 PAIN IS THE MOST COMMON TREATABLE SYMPTOM OF CANCER CURRENT EVIDENCE BASED CONCEPTS: MANAGEMENT OF CANCER PAIN PAIN AN UNMET CLINICAL NEED IN
Pain is a frequent complication of cancer, and is common in many other life-limiting illnesses MANAGEMENT OF CANCER PAIN A/Prof Ghauri Aggarwal FRACP, FAChPM, FFPMANZCA Palliative Medicine Physician Sydney
More informationINFORMATION FOR PATIENTS. Let s Manage Pain
INFORMATION FOR PATIENTS Let s Manage Pain 1 About this booklet Persistent pain, also called chronic pain, is pain which continues for longer than expected. Pain can affect all areas of your life. People
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationOpioid Type Pain Killers
Opioid Type Pain Killers Information for patients, relatives and carers For more information, please contact: Palliative Care Team 01904 725835 (York) 01723 342446 (Scarborough) Renal Department 01904
More informationNHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery
Acute Sector NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery Co-ordinators: Dr Karen Cranfield, Consultant Anaesthetist, Lead Acute Pain Sector
More informationRegional Renal Training
Regional Renal Training Palliative and End of Life Care Dr Clare Kendall North Bristol NHS Trust Advanced Kidney Disease Dialysis/Transplant Conservative Management Deteriorating despite dialysis/failing
More informationVolume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationEvidence-based Clinical Practice Guidelines on Management of Pain in Older People Aza Abdulla, Margaret Bone, Nicola Adams, Alison M.
Evidence-based Clinical Practice Guidelines on Management of Pain in Older People Aza Abdulla, Margaret Bone, Nicola Adams, Alison M. Elliott, Derek Jones, Roger Knaggs, Denis Martin, Elizabeth L. Sampson,
More informationSlow Release Opioids. Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Slow Release Opioids Morphine (Zomorph/MST) Oxycodone (Longtec, Oxycontin) Tapentadol (Palexia) For
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationStrong opioids for palliative care patients
Other formats Strong opioids for palliative care patients If you need this information in another format such as audio tape or computer disk, Braille, large print, high contrast, British Sign Language
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More information7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia
Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationSCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults
SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults BACKGROUND The justification for developing these guidelines lies
More informationThe NICE revised guidelines for the management of non-specific low back pain and; Implications for Practice
The NICE revised guidelines for the management of non-specific low back pain and; Implications for Practice David Walsh David.walsh@nottingham.ac.uk National Clinical Guideline Centre Commissioned by NICE
More informationStrong Opioid Guidelines for the treatment of chronic non-malignant pain
Strong Opioid Guidelines for the treatment of chronic non-malignant pain Effective Date: December 2011 Reviewed: March 2014 Next review date: March 2016 This guideline has been prepared and approved for
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationGuideline scope Persistent pain: assessment and management
National Institute for Health and Clinical Excellence [document type for example, IFP, QRG] on [topic] Document cover sheet Date Version number Editor 30/08/2017 1 NGC Action 1 2 3 4 5 6 7 8 9 10 11 12
More informationEnhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice
Enhanced Community Palliative Support Services Lynne Ghasemi St Luke s Hospice Learning Outcomes Define the different types of pain Describe the process of pain assessment Discuss pharmacological management
More informationNHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5
NHS...... Grampian Acute Sector NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults Co-ordinators: Consultant Anaesthetist, Lead Acute Pain
More informationAnalgesics: Management of Pain In the Elderly Handout Package
Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed
More informationDrugs used for the treatment of pain Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous
Drugs used for the treatment of Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous Adjuvant analgesics Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
More informationPain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017
Pain management in Paediatric Palliative Care Dr Jane Nakawesi 14 th August 2017 Content Management of pain in children Non pharmacological Pharmacological Exit level outcomes The participants will: Know
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationANAESTHESIA & PAIN MANAGEMENT FOR KNEE REPLACEMENT
BEFORE SURGERY ANAESTHESIA & PAIN MANAGEMENT FOR KNEE REPLACEMENT FASTING INSTRUCTIONS No food for 6 hours before your operation. It is okay to drink clear fluids up to 2 hours before surgery (water, clear
More informationPrimary Care Constipation Guidelines. Version 1 November 2016
Primary Care Constipation Guidelines Version 1 November 2016 VERSION CONTROL Version Date Amendments made Version 1 November 2016 New guideline Contents 1. Management of constipation in adults: acute and
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationPain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan
Pain management in palliative care Dr. Stepanie Lippett and Sister Karen Davies-Linihan contents Concept of total pain Steps in pain management Recognising neuropathic pain WHO analgesic ladder Common
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationPOLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy
POLICY DOCUMENT Document Title Reference Number PRESCRIBING FOR PAIN MANAGEMENT IN OPIOID DEPENDENT CLIENTS CG/pain management in opioid dependency/03/15 Policy Type Clinical Guideline Electronic File/Location
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationTreat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve
Treat primary symptoms Background information for clinicians Offer general lifestyle advice Background information for patients Manage IBS according to the dominant symptom Provenance Psychological symptoms
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationUnderstanding your take home medications from the surgical ward. Information for Patients
Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for
More information9/30/2017. Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management. Program Objectives. Impact of Poorly Managed Pain
Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management MARY BETH PARTYKA MSN ADULT NURSE PRACTITIONER ADVOCATE CHRIST MEDICAL CENTER ADULT PAIN SERVICE Program Objectives Identify
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationPAIN TERMINOLOGY TABLE
PAIN TERMINOLOGY TABLE TERM DEFINITION HOW TO USE CLINICALLY Acute Pain Pain that is usually temporary and results from something specific, such as a surgery, an injury, or an infection Addiction A chronic
More informationNeuropathic Pain. Griffith Research Online. Author. Published. Journal Title. Copyright Statement. Downloaded from. Link to published version
Griffith Research Online https://research-repository.griffith.edu.au Neuropathic Pain Author Hall, Tony Published 2010 Journal Title Australian Journal of Pharmacy Copyright Statement Copyright 2010 Australian
More information